Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
What is your first line treatment of choice for advanced (stage IIIA) follicular lymphoma, histologic grade 1-2 in an otherwise young healthy patient in 2019?
Assuming the patient has an indication for treatment.
Related Questions
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
What are the most important factors that you use to decide between R-CHOP vs R-miniCHOP in elderly or frail patients with DLBCL?
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
How would you treat a BTKi naive p53 mutated MCL in 1st relapse with disease noted both systemically and in the CNS?
How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
When would you consider using a BTK inhibitor in the frontline setting for lymphoplasmacytic lymphoma (LPL) or Waldenstrom's Macroglobulinemia?
Would you offer XRT as bridging for all patients with limited pre CAR-T disease or as consolidation for only those with residual PET-avidity on day+30 post CAR-T?
Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?
What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?